Asahi Kasei Pharma Denmark A/S: Financial statements 2023
CVR: 40948074
Source: annual report 2023, Danish Business Authority
01/04/2022 – 31/03/2023
Asahi Kasei Pharma Denmark A/S (CVR 40948074) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK -940,958 and a net result of DKK 18,232,738 compared with DKK 4,670,489 the year before. Equity in the 2023 report amounted to DKK 925,892,619. The solvency ratio was 99.5%.
- Gross Profit
- DKK -940,958
- Profit/Loss
- DKK 18,232,738
- Equity
- DKK 925,892,619
- Total Assets
- DKK 930,141,965
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | -941K | 18.2M | 925.9M | 0 |
| 2022 | - | -1.2M | 4.7M | 907.7M | 0 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationAbout Asahi Kasei Pharma Denmark A/S
Asahi Kasei Pharma Denmark A/S is a Danish company of the type Aktieselskab based in Nordhavn, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named River Forest A/S. The management consists of Daisuke Matsuo. The board consists of Masaya Etoh (chair), Daisuke Matsuo and Kenro Yuzaki. The company is owned by Asahi Kasei Corporation. According to the 2026 annual report, the company had an average of 0 employees. In 2026, the company reported a gross profit of DKK -793,488 and a net result of DKK 25,833,192 compared with DKK 26,072,771 the year before. Equity in the 2026 report amounted to DKK 1,003,291,531.
